Preclinical mouse cancer models: a maze of opportunities and challenges

Area of Science:

• Oncology
• Translational Medicine
• Drug Development

Background:

• Targeted cancer therapies have shown promise, revolutionizing treatment for certain cancers.
• However, a significant majority of novel cancer drugs fail during clinical trials, primarily due to lack of efficacy.
• This high failure rate highlights limitations in current preclinical evaluation methods.

Purpose of the Study:

• To review the current status, promise, and challenges of preclinical evaluation in advanced mouse cancer models.
• To discuss the limitations of existing preclinical methods in predicting clinical efficacy.
• To briefly introduce emerging models for early-stage preclinical development.

Main Methods:

• Exploration of advanced mouse cancer models used in preclinical drug evaluation.
• Analysis of factors contributing to the failure of cancer drug candidates.
• Brief overview of novel and emerging preclinical models.

Main Results:

• Current preclinical methods, particularly those using advanced mouse models, have limitations in accurately predicting the efficacy of novel cancer therapeutics.
• The low approval rate of new cancer drugs underscores the need for improved preclinical assessment strategies.
• Emerging models show potential for enhancing early-stage preclinical development and prediction of treatment outcomes.

Conclusions:

• There is a critical need to improve preclinical evaluation strategies to increase the success rate of novel cancer drug development.
• Advanced mouse cancer models offer valuable insights but require further refinement to better predict clinical outcomes.
• Emerging preclinical models may provide more accurate predictions, potentially reducing financial costs and improving patient quality of life by accelerating the development of effective cancer treatments.